Risk factors associated with extraintestinal manifestations in children with inflammatory bowel disease

2019 ◽  
Vol 74 (5) ◽  
pp. 691-697 ◽  
Author(s):  
Shlomi Cohen ◽  
Jacqueline Padlipsky ◽  
Anat Yerushalmy-Feler
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Extraintestinal Manifestations ◽  
Factors Associated ◽  
Inflammatory Bowel

scholarly journals Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease

2020 ◽  
Vol 27 (1) ◽  
pp. 58-64
Author(s):  
Heather Carney ◽  
Ruth Ann Marrie ◽  
James M Bolton ◽  
Scott B Patten ◽  
Lesley A Graff ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Substance Use ◽  
Anxiety Disorder ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Primary Care Providers ◽  
Care Providers ◽  
Factors Associated ◽  
Inflammatory Bowel

Abstract Background Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort. Methods Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants’ sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling. Results Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17–7.50), male sex (aOR, 2.44; 95% CI, 1.11–5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08–5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01–1.16). Conclusions One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.

Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort

2011 ◽  
Vol 106 (1) ◽  
pp. 110-119 ◽  
Author(s):  
Stephan R Vavricka ◽  
Lionel Brun ◽  
Pierluigi Ballabeni ◽  
Valérie Pittet ◽  
Bettina Mareike Prinz Vavricka ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Extraintestinal Manifestations ◽  
Inflammatory Bowel

scholarly journals Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
William Gillespie ◽  
Neil Marya ◽  
Julien Fahed ◽  
Gregory Leslie ◽  
Krunal Patel ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Retrospective Study ◽  
Clostridium Difficile ◽  
Bowel Disease ◽  
Biologic Therapy ◽  
Antibiotic Use ◽  
Extraintestinal Manifestations ◽  
Chi Squared ◽  
Inflammatory Bowel

Aim. To investigate the epidemiology and risk factors of Clostridium difficile infections (CDI) in patients with inflammatory bowel disease (IBD). Methods. This is a retrospective study of patients diagnosed with IBD. 1006 charts were screened and 654 patients met the inclusion criteria. Patients were divided into 2 cohorts based on the presence of prior diagnosis of CDI. Statistical analysis with Pearson’s chi-squared and two-sample t-test was performed. Results. The incidence of CDI among IBD patients was 6.7%. There was equal prevalence of CDI among Crohn’s disease (CD) (n=21, 49%) and ulcerative colitis (UC) (n=22, 51%). IBD patients acquired CDI at a mean age of 42.7 years, with 56% of infections acquired in the community and only 28% associated with healthcare. Only 30% of IBD patients with CDI had prior antibiotic use, and 16% had prior steroid use. IBD patients were significantly more likely to require biologic therapy (57% versus 37%, p<0.01) and have extraintestinal manifestations of IBD (43% versus 28%, p<0.02). Conclusions. IBD patients are more susceptible to CDI at a younger age and often lack traditional risk factors. IBD patients with at least one CDI were more likely to require biologic therapy and had greater rates of extraintestinal manifestations.

Sa509 RISK FACTORS ASSOCIATED WITH FAMILIAL INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 160 (6) ◽  
pp. S-528
Author(s):  
Catarina F. Gomes ◽  
Camilla Bjorn Jensen ◽  
Kristine Allin ◽  
Joana Torres ◽  
Johan M. Burisch
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Factors Associated ◽  
Inflammatory Bowel

Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse

2019 ◽  
Vol 26 (9) ◽  
pp. 1401-1406 ◽  
Author(s):  
Tawnya M Hansen ◽  
Brigitte C Sabourin ◽  
Banke Oketola ◽  
Charles N Bernstein ◽  
Harminder Singh ◽  
...  
Keyword(s):  
Mental Health ◽  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Logistic Regression ◽  
Depressive Symptoms ◽  
Bowel Disease ◽  
Substance Misuse ◽  
Cannabis Use ◽  
Factors Associated ◽  
Inflammatory Bowel

Abstract Background It is unknown whether cannabis users self-medicating their inflammatory bowel disease (IBD) symptoms are more likely to have comorbid mental health or personality risk factors associated with an increased potential for substance misuse compared with recreational cannabis users. Methods We surveyed individuals with IBD about their cannabis use, their mental health symptoms, and personality risk factors associated with substance misuse. We compared risk factors for substance misuse between individuals using cannabis to manage IBD symptoms and those using cannabis recreationally. Results Of 201 persons with IBD who completed the questionnaire, 108 reported lifetime cannabis use. Of those, a larger proportion of Crohn’s disease patients used cannabis to manage IBD symptoms (53% [34/64] vs 28% [12/43]; P = 0.010). Individuals self-medicating with cannabis were more likely to use cannabis for coping reasons (P = 0.016) and demonstrated higher levels of impulsivity (P = 0.004) and depressive symptoms (P = 0.012) when compared with individuals using cannabis recreationally. Logistic regression revealed that cannabis was 4.1 times (P = 0.05) and 3.7 times (P = 0.05) more likely to be used for IBD symptoms by smokers and individuals with moderate–severe depressive symptoms, respectively. Individuals high in impulsivity were 4.1 times more likely to use cannabis for their IBD symptoms than those low in impulsivity (P = 0.005). Conclusions Persons with IBD self-medicating with cannabis have characteristics associated with increased vulnerability to substance misuse when compared with those using cannabis recreationally. Screening for mental health comorbidities and vulnerability to substance misuse should be undertaken if cannabis is to be used to treat IBD symptoms.

Sign in / Sign up

Export Citation Format

Share Document